150 related articles for article (PubMed ID: 36446644)
1. Clinical Value of FDG-PET/CT in Multiple Myeloma: An Update.
Bezzi D; Ambrosini V; Nanni C
Semin Nucl Med; 2023 May; 53(3):352-370. PubMed ID: 36446644
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma.
Nanni C; Zamagni E
PET Clin; 2019 Jul; 14(3):383-389. PubMed ID: 31084777
[TBL] [Abstract][Full Text] [Related]
3.
Morales-Lozano MI; Rodriguez-Otero P; Sancho L; Nuñez-Cordoba JM; Prieto E; Marcos-Jubilar M; Rosales JJ; Alfonso A; Guillen EF; San-Miguel J; Garcia-Velloso MJ
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077292
[TBL] [Abstract][Full Text] [Related]
4. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
[TBL] [Abstract][Full Text] [Related]
5. Role of
Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
[TBL] [Abstract][Full Text] [Related]
6. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
Sachpekidis C; Goldschmidt H; Dimitrakopoulou-Strauss A
Molecules; 2019 Dec; 25(1):. PubMed ID: 31905752
[TBL] [Abstract][Full Text] [Related]
7. Comparative Performance of Whole-Body MRI and FDG PET/CT in Evaluation of Multiple Myeloma Treatment Response: Systematic Review and Meta-Analysis.
Rama S; Suh CH; Kim KW; Durieux JC; Ramaiya NH; Tirumani SH
AJR Am J Roentgenol; 2022 Apr; 218(4):602-613. PubMed ID: 34704461
[No Abstract] [Full Text] [Related]
8. ¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review.
van Lammeren-Venema D; Regelink JC; Riphagen II; Zweegman S; Hoekstra OS; Zijlstra JM
Cancer; 2012 Apr; 118(8):1971-81. PubMed ID: 21887677
[TBL] [Abstract][Full Text] [Related]
9. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
Jamet B; Zamagni E; Nanni C; Bailly C; Carlier T; Touzeau C; Michaud AV; Moreau P; Bodet-Milin C; Kraeber-Bodere F
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751375
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG PET in the staging of multiple myeloma.
Vicentini JRT; Bredella MA
Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
[No Abstract] [Full Text] [Related]
11. 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma.
Chen M; Zhu W; Du J; Yang C; Han B; Zhou D; Huo L; Zhuang J
Sci Rep; 2021 Nov; 11(1):22188. PubMed ID: 34773054
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
13.
Hemrom A; Tupalli A; Alavi A; Kumar R
PET Clin; 2022 Jul; 17(3):415-430. PubMed ID: 35717100
[TBL] [Abstract][Full Text] [Related]
14. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe).
Nanni C; Versari A; Chauvie S; Bertone E; Bianchi A; Rensi M; Bellò M; Gallamini A; Patriarca F; Gay F; Gamberi B; Ghedini P; Cavo M; Fanti S; Zamagni E
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):712-719. PubMed ID: 29270787
[TBL] [Abstract][Full Text] [Related]
15. [PET-CT for nuclear medicine diagnostics of multiple myeloma].
Dimitrakopoulou-Strauss A
Radiologe; 2014 Jun; 54(6):564, 566-71. PubMed ID: 24890842
[TBL] [Abstract][Full Text] [Related]
16. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
[TBL] [Abstract][Full Text] [Related]
18. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Multiple Myeloma.
Murtazaliev S; Rowe SP; Sheikhbahaei S; Werner RA; Sólnes LB
PET Clin; 2024 Apr; 19(2):249-260. PubMed ID: 38199914
[TBL] [Abstract][Full Text] [Related]
19. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
20. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.
Li Y; Liu J; Huang B; Chen M; Diao X; Li J
Oncotarget; 2017 Apr; 8(15):25637-25649. PubMed ID: 27556189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
